VERAXA Biotech AG (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, announced it has initiated cell line development for its lead BiTAC(R) T-cell engager (BiTAC-TCE) program, selecting ATUM, a U.S.-based contract research organization, to support manufacturing development. The collaboration marks a critical milestone as the candidate advances toward IND/CTA-enabling studies.
ATUM will apply its proprietary Leap-In Transposase(R) technology to generate stable clonal cell lines for VERAXA’s lead therapeutic candidate. This partnership is intended to support manufacturing, analytical development, and nonclinical studies required before clinical testing can begin.
VERAXA’s BiTAC(R) platform is designed to improve the selectivity of T-cell engagers, potentially reducing toxicity associated with conventional approaches. By engineering bispecific antibodies that engage T cells more precisely, the platform aims to enhance anti-tumor activity while minimizing off-target effects. The advancement of this lead program represents a significant step for the company as it moves toward clinical development.
The company recently expanded its research facilities in Heidelberg, Germany, increasing laboratory capacity as multiple oncology programs progress toward clinical trials. This expansion underscores VERAXA’s commitment to advancing its pipeline of novel cancer therapies.
According to VERAXA, the partnership with ATUM is intended to ensure robust cell line development for the production of its BiTAC-TCE candidate. Stable cell lines are essential for consistent manufacturing of biologic drugs, which is a prerequisite for regulatory filings and eventual commercialization.
The announcement comes as VERAXA continues to build momentum in the competitive oncology space. The BiTAC platform, which leverages T-cell engager technology, is part of a broader trend in immunotherapy aimed at harnessing the body’s immune system to fight cancer. By focusing on selectivity, VERAXA hopes to address limitations of existing T-cell engagers, which can cause severe cytokine release syndrome and other toxicities.
Investors and industry observers are watching VERAXA’s progress closely. The company’s newsroom provides updates on VRXA developments at https://ibn.fm/VRXA. The successful completion of cell line development and subsequent IND/CTA-enabling studies could pave the way for first-in-human trials, a major catalyst for the company.
VERAXA’s partnership with ATUM highlights the importance of specialized contract research organizations in advancing biotech pipelines. ATUM’s Leap-In Transposase technology is a proprietary method for generating high-yielding stable cell lines, which can accelerate development timelines and reduce manufacturing risks.
As VERAXA moves its lead BiTAC-TCE program toward the clinic, the implications for patients with difficult-to-treat cancers could be significant. If successful, the platform may offer a new option with improved safety and efficacy compared to existing immunotherapies.
This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is VERAXA Biotech Advances Lead Cancer Drug Candidate with ATUM Cell Line Development Partnership.